BiotechTube

Abciximab local infusion

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
15
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Acute Anterior Myocardial Infarction

Conditions

Acute Anterior Myocardial Infarction

Trial Timeline

Sep 1, 2009 → Apr 1, 2013

NCT ID
NCT00976521

About Abciximab local infusion

Abciximab local infusion is a pre-clinical stage product being developed by Atrium Therapeutics for Acute Anterior Myocardial Infarction. The current trial status is completed. This product is registered under clinical trial identifier NCT00976521. Target conditions include Acute Anterior Myocardial Infarction.

Hype Score Breakdown

Clinical
5
Activity
2
Company
2
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT00976521Pre-clinicalCompleted

Competing Products

20 competing products in Acute Anterior Myocardial Infarction

See all competitors
ProductCompanyStageHype Score
AFM28AffimedPhase 1
25
TRV130 1.5 mg + TRV130 3 mg + TRV130 4.5 mg + Morphine 10 mg + PlaceboTrevenaPhase 1
25
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + PlaceboTrevenaPhase 2
44
Oliceridine + Placebo + MorphineTrevenaPhase 3
69
Oliceridine + Placebo + MorphineTrevenaPhase 3
69
TRV130TrevenaPhase 3
69
TRV130 + Morphine + PlaceboTrevenaPhase 2
44
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenCSPC Pharmaceutical Group LimitedPhase 2
51
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
51
SPT-07A injectionSinopharmPhase 3
76
PRGN-3006 T CellsPrecigenPhase 1
28
BisantreneRace OncologyPhase 2
44
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridineRace OncologyPhase 1
25
Bisantrene + Fludarabine + ClofarabineRace OncologyPhase 2
44
ZN-d5 ZN-c3 + ZN-c3Zentalis PharmaceuticalsPhase 1/2
33
ZN-d5Zentalis PharmaceuticalsPhase 1
25
VIP943 (QW) + VIP943 (BIW)Vincerx PharmaPhase 1
25
LY2523355Eli LillyPhase 1
33
TomivosertibeFFECTOR TherapeuticsPhase 1
25
gemtuzumab ozogamycinChugai PharmaceuticalPhase 3
77

Other Products from Atrium Therapeutics

Rivastigmine + Placebo (for rivastigmine)Approved
77
Phenoxybenzamine + DoxazosinApproved
77
Ropivacaine HCL + Exparel + Epinephrine + Clonidine HCL + KetorolacPhase 3
69
Metformin Hydrochloride ERPhase 2
44
DiclofenacPhase 2
44